CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million.

The company released its annual results, reporting group revenue of RMB 269.574 billion, a year-on-year increase of 4.62%. Profit attributable to shareholders reached RMB 4.045 billion, up 20.73% compared to the previous year. Earnings per share were RMB 0.64. A final dividend of RMB 0.122 per share was declared, representing an increase of approximately 135% year-on-year.

At the business level, the pharmaceutical segment recorded revenue of RMB 51.039 billion, growing 10.2% year-on-year, with significant growth in traditional Chinese medicine, biologics, nutritional supplements, and other segments. The pharmaceutical distribution business generated revenue of RMB 220.08 billion, up 3.2% year-on-year. Revenue from pharmaceutical retail operations reached RMB 12.21 billion, increasing 20.8% year-on-year, driven by strong growth in the Direct-to-Patient (DTP) business.